MMP9 processing of HSPB1 regulates tumor progression

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Choi, Seo Hyun ^a,b   Lee, Hae June ^a   Jin, Yeung Bae ^a   Jang, Junho ^a   Kang, Ga Young ^c   Lee, Minyoung ^a   Kim, Chun Ho ^a   Kim, Joon ^b   Yoon, Sam S ^d   Lee, Yun Sil ^c   Lee, Yoon Jin ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea University   (South Korea)

^c Ewha Womans University   (South Korea)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; HEAT SHOCK PROTEIN 27; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; HSPB1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL ACTIVATION; COLON CARCINOMA; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIVER TUMOR; LUNG TUMOR; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TRANSCRIPTION REGULATION; WILD TYPE; ADENOCARCINOMA; ANIMAL; CARCINOGENESIS; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SARCOMA; SOFT TISSUE TUMOR;

ADENOCARCINOMA; ANIMALS; CARCINOGENESIS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIAL CELLS; HSP27 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICE; PHOSPHORYLATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84908308383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085509     Document Type: Article

References (50)

1. Richter K, Haslbeck M, Buchner J (2010) The heat shock response: life on the verge of death. Mol Cell 40: 253-266.
2. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, et al. (2007) Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 448: 474-479. (Pubitemid 47123511)
3. Didelot C, Schmitt E, Brunet M, Maingret L, Parcellier A, et al. (2006) Heat shock proteins: endogenous modulators of apoptotic cell death. Molecular Chaperones in Health and Disease: 171-198.
4. McDonald ET, Bortolus M, Koteiche HA, McHaourab HS (2012) Sequence, structure, and dynamic determinants of Hsp27 (HspB1) equilibrium dissociation are encoded by the N-terminal domain. Biochemistry 51: 1257-1268.
5. Liao WC, Wu MS, Wang HP, Tien YW, Lin JT (2009) Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 38: 422-426.
6. Huang Q, Ye J, Chen W, Wang L, Lin W, et al. (2010) Heat shock protein 27 is over-expressed in tumor tissues and increased in sera of patients with gastric adenocarcinoma. Clin Chem Lab Med 48: 263-269.
7. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C (2007) Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81: 15-27. (Pubitemid 46021247)
8. Lee Y, Lee D, Cho C, Chung H, Bae S, et al. (2005) HSP25 inhibits radiation-induced apoptosis through reduction of PKC¥ä-mediated ROS production. Oncogene 24: 3715-3725. (Pubitemid 40826871)
9. Lee YJ, Lee DH, Cho CK, Bae S, Jhon GJ, et al. (2005) HSP25 inhibits protein kinase C delta-mediated cell death through direct interaction. J Biol Chem 280: 18108-18119. (Pubitemid 41389056)
10. Evans IM, Britton G, Zachary IC (2008) Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial tubulogenesis via protein kinase D and independent of p38 kinase. Cell Signal 20: 1375-1384.
11. Lee YJ, Lee HJ, Choi SH, Jin YB, An HJ, et al. (2012) Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction. Angiogenesis 15: 229-242.
12. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174. (Pubitemid 37328786)
13. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, et al. (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68. (Pubitemid 10098769)
14. Deraz EM, Kudo Y, Yoshida M, Obayashi M, Tsunematsu T, et al. (2011) MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PLoS One 6: e25438.
15. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48: 411-424. (Pubitemid 39360392)
16. Overall CM, Kleifeld O (2006) Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239. (Pubitemid 43292566)
17. Overall CM (2004) Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem J 383: e5-7.
18. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812. (Pubitemid 29291347)
19. Overall CM, Kleifeld O (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94: 941-946.
20. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064-1072.
21. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, et al. (2007) A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13: 992-997. (Pubitemid 47222037)
22. Hwang SJ, Kim SH, Kim HZ, Steinmetz MO, Koh GY, et al. (2008) High-level expression and purification of a designed angiopoietin-1 chimeric protein, COMP-Ang1, produced in Chinese hamster ovary cells. Protein J 27: 319-326.
23. Lee YJ, Koch M, Karl D, Torres-Collado AX, Fernando NT, et al. (2010) Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res 70: 948-956.
24. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, et al. (2000) Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105. (Pubitemid 32059190)
25. Ren H, Du N, Liu G, Hu HT, Tian W, et al. (2006) Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol 12: 2789-2792. (Pubitemid 43796495)
26. Berrieman HK, Cawkwell L, O'Kane SL, Smith L, Lind MJ (2006) Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer. Oncol Rep 15: 283-286.
27. Genersch E, Hayess K, Neuenfeld Y, Haller H (2000) Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 113 Pt 23: 4319-4330. (Pubitemid 32004642)
28. Goerge T, Barg A, Schnaeker EM, Poppelmann B, Shpacovitch V, et al. (2006) Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 66: 7766-7774. (Pubitemid 44289237)
29. Vallon M, Essler M (2006) Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta3 to glycosaminoglycans. J Biol Chem 281: 34179-34188. (Pubitemid 46036626)
30. Rambaruth ND, Greenwell P, Dwek MV (2012) The lectin Helix pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human breast cancer. Glycobiology 22: 839-848.
31. Lee YJ, Lee HJ, Choi SH, Jin YB, An HJ, et al. (2012) Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction. Angiogenesis.
32. Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, et al. (2003) Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44: 560-566. (Pubitemid 37328632)
33. Jimenez RE, Hartwig W, Antoniu BA, Compton CC, Warshaw AL, et al. (2000) Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control. Ann Surg 231: 644-654. (Pubitemid 30249825)
34. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, et al. (2008) Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 8: 286.
35. Guo K, Kang NX, Li Y, Sun L, Gan L, et al. (2009) Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC Cancer 9: 100.
36. Marquez E, Sadowski E, Reese S, Vidyasagar A, Artz N, et al. (2012) Serum HSP27 is associated with medullary perfusion in kidney allografts. J Nephrol: 0.
37. Lebherz-Eichinger D, Ankersmit HJ, Hacker S, Hetz H, Kimberger O, et al. (2012) HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clin Chim Acta 413: 282-286.
38. De AK, Roach SE (2004) Detection of the soluble heat shock protein 27 (hsp27) in human serum by an ELISA. J Immunoassay Immunochem 25: 159-170. (Pubitemid 38581602)
39. Martin-Ventura JL, Nicolas V, Houard X, Blanco-Colio LM, Leclercq A, et al. (2006) Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler Thromb Vasc Biol 26: 1337-1343. (Pubitemid 44305379)
40. Guo H, Bai Y, Xu P, Hu Z, Liu L, et al. (2010) Functional promoter -1271G>C variant of HSPB1 predicts lung cancer risk and survival. J Clin Oncol 28: 1928-1935.
41. Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, et al. (2004) HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up. Eur J Gynaecol Oncol 25: 165-168. (Pubitemid 38268689)
42. Missotten GS, Journee-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, et al. (2003) Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci 44: 3059-3065. (Pubitemid 36759773)
43. Folkman J, Kalluri R (2004) Cancer without disease. Nature 427: 787. (Pubitemid 38297724)
44. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, et al. (2000) Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6: 4628-4634. (Pubitemid 32110397)
45. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285. (Pubitemid 28015876)
46. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, et al. (2010) Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115: 4605-4613.
47. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672. (Pubitemid 37328917)
48. Kruger A, Kates RE, Edwards DR (2010) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803: 95-102.
49. Okazaki I (2012) Novel Cancer-targeting Agents/Application Strategies Developed from MMP Science. Anticancer Agents Med Chem.
50. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, et al. (2001) Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 276: 43503-43508.